Metabolic Profile, Weight Increases Assessed in Ziprasidone Augmentation for Major Depressive Disorder

This article originally appeared here.
Share this content:
Escitalopram plus ziprasidone may lead to weight gain and akathisia and require additional monitoring of patients with major depressive disorder.
Escitalopram plus ziprasidone may lead to weight gain and akathisia and require additional monitoring of patients with major depressive disorder.

Escitalopram plus adjunctive ziprasidone may lead to weight gain and akathisia and require additional monitoring of patients with major depressive disorder (MDD), but ziprasidone augmentation appears safe overall, according to research published in the Journal of Clinical Psychiatry.

David Mischoulon, MD, PhD, from the Depression Clinical and Research Program at Massachusetts General Hospital in Boston, and colleagues conducted a randomized, double-blind, placebo-controlled study of patients with persistent MDD (Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder That Do Not Sufficiently Respond to Treatment With SSRIs; ClinicalTrials.gov identifier: NCT00633399). Outpatients (n=139) were recruited after an 8-week open-label trial of escitalopram.

During the initial 8-week study period, participants from 3 academic medical centers in Boston, Massachusetts; Birmingham, Alabama; and Nashville, Tennessee, received escitalopram 10 to 30 mg/day. During the first 4 weeks, escitalopram doses increased by 10 mg/week, stabilizing at week 4. After enrollment in the 8-week open-label expansion, participants randomly received either adjunctive ziprasidone (escitalopram plus ziprasidone 20-80 mg twice daily; n=71) or escitalopram plus placebo (n=68). Mean doses of escitalopram were 21±5.8 mg/day and 19.2±3.1 mg/day in the ziprasidone and placebo groups, respectively.

BMI, weight, low-density lipoprotein-cholesterol and high-density lipoprotein-cholesterol, triglycerides, fasting glucose, HbA1c, thyroid-stimulating hormone, and prolactin levels were assessed at baseline and again at the conclusion of the double-blind phase. Measurements for all parameters were comparable at baseline between both groups (P >.05). No significant changes were recorded in most measures by week 8, although ziprasidone therapy resulted in a "significantly greater" weight increase than placebo (net difference, 2.5 kg; P =.03).

Although baseline QTc measures were also similar between groups, QTc increased by a mean 8.8 milliseconds by week 8 in the ziprasidone group (P =.06), so a significant association was noted between ziprasidone dose and QTc prolongation.

Patients in the ziprasidone group experienced a significantly higher baseline Barnes Akathisia Scale score for 1 item (objective); the other 3 items (subjective awareness of restlessness, distress related to restlessness, and global clinical assessment of akathisia) were similar between groups. During the study period, Barnes Akathisia Scale scores for item 4 increased in the ziprasidone group and decreased in the placebo group (P =.01).

"Adjunctive ziprasidone when combined with the [selective serotonin reuptake inhibitor (SSRI)] escitalopram in MDD patients...demonstrated a mild increase in QTc that is deemed unlikely to be of broad clinical relevance," the researchers wrote. "The positive efficacy findings for this combination supported its use as an effective augmentation of an SSRI, and our current results also support relative safety of the combination therapy."

"However, in view of the developing concerns and warning about SSRIs and QTc prolongation, clinicians should carefully weigh the pros and cons of this combination," they concluded.

Study Limitations

  • The current study focused on efficacy, safety, and tolerability of adjunctive ziprasidone; it is unclear whether results would have been different if other antidepressants were used in conjunction with ziprasidone.
  • Multiple inclusion and exclusion criteria were included in the current study, and it is unknown whether more cardiovascular or metabolic effects would have been seen in patients who did not meet inclusion criteria.

Drs Mischoulon, Shelton, Bobo, Fava, and Papakostas report receiving a variety of research support, consulting, and speaking honoraria and grant funding from Pfizer and Forest Pharmaceuticals.

Reference

Mischoulon D, Shelton R, Baer L, et al. Ziprasidone augmentation of escitalopram for major depressive disorder: cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. doi: 10.4088/JCP.15m10426


You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus